A quantitative NMR protocol for the simultaneous analysis of atropine and obidoxime in parenteral injection devices.
A rapid selective and accurate quantitative (1)H NMR method was developed for the simultaneous analysis of obidoxime chloride and atropine sulfate, the active components in parenteral injection devices (PID) used for the emergency treatment of poisoning by toxic organophosphates. The spectra were acquired in 90% H(2)O-10% D(2)O using sodium 3-(trimethylsilyl)-1-propane sulfonate hydrate as the internal standard. Both synthetic mixtures and dosage forms were assayed. The results were compared with those obtained from a reported HPLC method.
Sharma
Radha
R
Defence Research and Development Establishment, Gwalior, India.
Gupta
Pradeep K
PK
Mazumder
Avik
A
Dubey
Devendra K
DK
Ganesan
Kumaran
K
Vijayaraghavan
R
R
D000465:Algorithms; D017738:Alkanesulfonic Acids; D001285:Atropine / Q000032:analysis*; D002801:Cholinesterase Reactivators / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D007263:Infusions, Parenteral; D009682:Magnetic Resonance Spectroscopy; D008970:Molecular Weight; D018727:Muscarinic Antagonists / Q000032:analysis*; D009768:Obidoxime Chloride / Q000032:analysis*; D019999:Pharmaceutical Solutions; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet; D014297:Trimethylsilyl Compounds
D017738:Alkanesulfonic Acids; D002801:Cholinesterase Reactivators; D018727:Muscarinic Antagonists; D019999:Pharmaceutical Solutions; D014297:Trimethylsilyl Compounds; C009580:3-(trimethylsilyl)propanesulfonic acid; D009768:Obidoxime Chloride; D001285:Atropine